NIH clinical trial testing antiviral remdesivir plus anti-inflammatory drug baricitinib for COVID-19 begins

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).

 

05/08/2020 01:45 PM EDT

The trial is now enrolling hospitalized adults with COVID-19 in the United States.

This email was sent to ymilov@gmail.com using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) · 9000 Rockville Pike · Bethesda MD 20892 · 301-496-4000 / TTY 301-402-9612 GovDelivery logo